vibostolimab + pembrolizumab + 5-fluorouracil + cisplatin

This drug is a **combination therapy** consisting of four active agents: **vibostolimab**, **pembrolizumab**, **5-fluorouracil**, and **cisplatin**. Vibostolimab is an investigational anti-TIGIT monoclonal antibody that blocks the TIGIT receptor to restore antitumor activity. Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor monoclonal antibody, approved for multiple cancer indications as an immunotherapy agent. 5-fluorouracil is a cytotoxic antimetabolite chemotherapy that inhibits thymidylate synthase, disrupting DNA synthesis and repair. Cisplatin is a platinum-based chemotherapy that causes DNA crosslinking, leading to apoptosis of cancer cells. The combination seeks to leverage synergistic effects of immune checkpoint blockade (via TIGIT and PD-1 inhibition) with the established cytotoxic impact of 5-fluorouracil and cisplatin. This regimen is being investigated primarily in advanced cancers, such as metastatic or unresectable non-small cell lung cancer (NSCLC) and head and neck cancers, in clinical trials by Merck and collaborators[1][3][5].